![]() Trequinsin hydrochloride structure
|
Common Name | Trequinsin hydrochloride | ||
---|---|---|---|---|
CAS Number | 78416-81-6 | Molecular Weight | 441.95000 | |
Density | N/A | Boiling Point | 613.8ºC at 760 mmHg | |
Molecular Formula | C24H28ClN3O3 | Melting Point | N/A | |
MSDS | USA | Flash Point | 325ºC |
Use of Trequinsin hydrochlorideTrequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP phosphodiesterase (PDE), with an IC50 of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine[1][2][3]. |
Name | Trequinsin hydrochloride,2,3,6,7-Tetrahydro-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-4H-pyrimido[6,1-a]isoquinolin-4-onehydrochloride |
---|---|
Synonym | More Synonyms |
Description | Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of platelet CAMP phosphodiesterase (PDE), with an IC50 of 0.25 nM. Trequinsin hydrochloride (HL 725) is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Trequinsin hydrochloride exerts besides its cardiovascular and antihypertensive qualities very potent antiplatelet activities[1]. Trequinsin hydrochloride is an efficacious agonist of [Ca2+]i[3]. Cell Viability Assay[3] Cell Line: Samples from healthy volunteer research donors with normal sperm motility parameters in agreement with World Health Organization 2010 criteria. Concentration: 10 μM. Incubation Time: 20 min. Result: Caused a concentrationdependent increase in [Ca2+]i (EC50 = 6.4 μM [95% confidence interval (CI): 4.1-9.9 μM]). |
References |
Boiling Point | 613.8ºC at 760 mmHg |
---|---|
Molecular Formula | C24H28ClN3O3 |
Molecular Weight | 441.95000 |
Flash Point | 325ºC |
Exact Mass | 441.18200 |
PSA | 57.75000 |
LogP | 4.38670 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xi |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | UW7727000 |
~% Trequinsin hydr... CAS#:78416-81-6 |
Literature: Kienzle; Bounameaux; Minder; Muggli Helvetica Chimica Acta, 1986 , vol. 69, # 7 p. 1671 - 1680 |
~% Trequinsin hydr... CAS#:78416-81-6 |
Literature: Kienzle; Bounameaux; Minder; Muggli Helvetica Chimica Acta, 1986 , vol. 69, # 7 p. 1671 - 1680 |
~% Trequinsin hydr... CAS#:78416-81-6 |
Literature: Kienzle; Bounameaux; Minder; Muggli Helvetica Chimica Acta, 1986 , vol. 69, # 7 p. 1671 - 1680 |
Precursor 3 | |
---|---|
DownStream 0 |
Pituitary adenylate cyclase activating polypeptide (PACAP) potently enhances tyrosine hydroxylase (TH) expression in adrenal chromaffin cells.
Life Sci. 54(22) , 1735-43, (1994) In primary cultured bovine adrenal chromaffin cells (BACC), pituitary adenylate cyclase activating polypeptide 1-38 (PACAP) produced a dose related increase in tyrosine hydroxylase (TH) Vmax when meas... |
|
Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells.
J. Cardiovasc. Pharmacol. 24(3) , 351-7, (1994) Bovine aortic endothelial cells contain cyclic GMP-stimulated phosphodiesterase (PDE) regulating intracellular cyclic AMP and cyclic GMP levels. To investigate the roles of this PDE isoform for cyclic... |
|
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
J. Mol. Cell. Cardiol. 32(10) , 1831-40, (2000) Nitric oxide (NO) donors increase heart rate (HR) through a guanylyl cyclase-dependent stimulation of the pacemaker current I(f), without affecting basal I(Ca-L). The activity of I(f)is known to be en... |
trequinsine |
HL 725 HCL |
TREQUINSIN HYDROCHLORIDE MINIMUM |
TREQUINSIN HYDROCHLORIDE |
Trequinsin,HCl |
HL 725 |